scholarly journals Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

Leukemia ◽  
2015 ◽  
Vol 30 (3) ◽  
pp. 526-535 ◽  
Author(s):  
S Lonial ◽  
B Durie ◽  
A Palumbo ◽  
J San-Miguel
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Current Status ◽  
Future Perspectives

scholarly journals Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development

Antibodies ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 34 ◽  
Author(s):  
Ahmad Iftikhar ◽  
Hamza Hassan ◽  
Nimra Iftikhar ◽  
Adeela Mushtaq ◽  
Atif Sohail ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Combination Therapy ◽  
Immune Responses ◽  
Web Of Science ◽  
Cochrane Library ◽  
Future Perspectives ◽  
Antibody Drug Conjugate ◽  
Chemotherapy Agents

Background: Immunotherapy for multiple myeloma (MM) has been the focus in recent years due to its myeloma-specific immune responses. We reviewed the literature on non-Food and Drug Administration (FDA) approved monoclonal antibodies (mAbs) to highlight future perspectives. We searched PubMed, EMBASE, Web of Science, Cochrane Library and ClinicalTrials.gov to include phase I/II clinical trials. Data from 39 studies (1906 patients) were included. Of all the agents, Isatuximab (Isa, anti-CD38) and F50067 (anti-CXCR4) were the only mAbs to produce encouraging results as monotherapy with overall response rates (ORRs) of 66.7% and 32% respectively. Isa showed activity when used in combination with lenalidomide (Len) and dexamethasone (Dex), producing a clinical benefit rate (CBR) of 83%. Additionally, Isa used in combination with pomalidomide (Pom) and Dex resulted in a CBR of 73%. Indatuximab Ravtansine (anti-CD138 antibody-drug conjugate) produced an ORR of 78% and 79% when used in combination with Len-Dex and Pom-Dex, respectively. Conclusions: Combination therapy using mAbs such as indatuximab, pembrolizumab, lorvotuzumab, siltuximab or dacetuzumab with chemotherapy agents produced better outcomes as compared to monotherapies. Further clinical trials investigating mAbs targeting CD38 used in combination therapy are warranted.

Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives

Tumor Biology ◽  
2015 ◽  
Vol 37 (1) ◽  
pp. 127-140 ◽  
Author(s):  
Giandomenico Roviello ◽  
Karol Polom ◽  
Roberto Petrioli ◽  
Luigi Marano ◽  
Daniele Marrelli ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Monoclonal Antibodies ◽  
Current Status ◽  
Future Perspectives

Proteomic analysis of multiple myeloma: Current status and future perspectives

2011 ◽  
Vol 5 (1-2) ◽  
pp. 30-37 ◽  
Author(s):  
Feng Ge ◽  
Li-Jun Bi ◽  
Sheng-Ce Tao ◽  
Xu-dong Xu ◽  
Zhi-Ping Zhang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Proteomic Analysis ◽  
Current Status ◽  
Future Perspectives

Role of investigational monoclonal antibodies in the treatment of multiple myeloma: A systematic review.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e19533-e19533
Author(s):  
Hamza Hassan ◽  
Ahmad Iftikhar ◽  
Nimra Iftikhar ◽  
Adeela Mushtaq ◽  
Abdul Rafae ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Combination Therapy ◽  
Immune Responses ◽  
Web Of Science ◽  
Future Perspectives ◽  
Antibody Drug Conjugate ◽  
Important Target

e19533 Background: Immunotherapy for multiple myeloma (MM) has been of focus in recent years due to its myeloma-specific immune responses. We reviewed literature on non-FDA approved monoclonal antibodies (MoAbs) to highlight future perspectives. Methods: We searched PubMed, EMBASE, Web of Science, Cochrane and Clinicaltrilas.gov to include phase I/II clinical trials. Results: 40 studies (1917 patients) were included. Isatuximab (anti-CD38) and F50067 (anti-CXCR4) were the only MoAbs which produced encouraging results as monotherapy with ORR of 66.7% and 32% respectively. Isatuximab use in combination with Len-Dex produced CBR of 83%, and in combination with pomalidomide and dexamethasone CBR of 73%. Indatuximab Ravtansine, an antibody-drug conjugate, produced ORR 78% and 79% in combination with Len-Dex and pomalidomide + dexamethasone respectively. Conclusions: CD38 remains an important target for further clinical trials in combination therapy. Trials using indatuximab, pembrolizumab, lorvotuzumab, siltuximab, and dacetuzumab in combination therapy produced better outcomes as compared to monotherapies. [Table: see text]

Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives

2018 ◽  
Vol 23 (37) ◽  
pp. 5760-5765 ◽  
Author(s):  
Antonio Gambardella ◽  
Angelo Labate ◽  
Laura Mumoli ◽  
Iscia Lopes-Cendes ◽  
Fernando Cendes
Keyword(s):  
Drug Therapy ◽  
Antiepileptic Drug ◽  
Current Status ◽  
Future Perspectives ◽  
Antiepileptic Drug Therapy

Radio-localization of Non-Palpable Breast Lesions Under Ultrasonographic Guidance: Current Status and Future Perspectives

2017 ◽  
Vol 10 (3) ◽  
Author(s):  
Giulia Anna Follacchio ◽  
Francesco Monteleone ◽  
Maria Letizia Meggiorini ◽  
Maria Paola Nusiner ◽  
Carlo De Felice ◽  
...  
Keyword(s):  
Current Status ◽  
Breast Lesions ◽  
Future Perspectives ◽  
Radio Localization ◽  
Palpable Breast ◽  
Ultrasonographic Guidance
Sign in / Sign up

Export Citation Format

Share Document